| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 29/01/2025 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:BFRIW | Biofrontera Inc |
| 21/01/2025 | 15:24 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:BFRIW | Biofrontera Inc |
| 08/01/2025 | 15:50 | GlobeNewswire Inc. | Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) | NASDAQ:BFRIW | Biofrontera Inc |
| 23/12/2024 | 15:30 | GlobeNewswire Inc. | Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market | NASDAQ:BFRIW | Biofrontera Inc |
| 05/12/2024 | 14:56 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:BFRIW | Biofrontera Inc |
| 27/11/2024 | 15:26 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BFRIW | Biofrontera Inc |
| 22/11/2024 | 15:10 | GlobeNewswire Inc. | Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note | NASDAQ:BFRIW | Biofrontera Inc |
| 13/11/2024 | 23:16 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BFRIW | Biofrontera Inc |
| 13/11/2024 | 23:15 | GlobeNewswire Inc. | Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update | NASDAQ:BFRIW | Biofrontera Inc |
| 13/11/2024 | 20:12 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:BFRIW | Biofrontera Inc |
| 31/10/2024 | 15:32 | GlobeNewswire Inc. | Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) | NASDAQ:BFRIW | Biofrontera Inc |
| 14/10/2024 | 16:30 | GlobeNewswire Inc. | Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) | NASDAQ:BFRIW | Biofrontera Inc |
| 07/10/2024 | 14:45 | GlobeNewswire Inc. | FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment | NASDAQ:BFRIW | Biofrontera Inc |
| 12/09/2024 | 15:46 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:BFRIW | Biofrontera Inc |
| 14/08/2024 | 22:30 | GlobeNewswire Inc. | Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:BFRIW | Biofrontera Inc |
| 24/06/2024 | 14:30 | GlobeNewswire Inc. | Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp | NASDAQ:BFRIW | Biofrontera Inc |
| 22/05/2024 | 22:45 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BFRIW | Biofrontera Inc |
| 16/12/2022 | 14:30 | GlobeNewswire Inc. | Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders | NASDAQ:BFRIW | Biofrontera Inc |
| 30/11/2022 | 20:08 | GlobeNewswire Inc. | Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference | NASDAQ:BFRIW | Biofrontera Inc |
| 28/11/2022 | 17:05 | GlobeNewswire Inc. | BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022 | NASDAQ:BFRIW | Biofrontera Inc |
| 21/11/2022 | 14:48 | GlobeNewswire Inc. | Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk | NASDAQ:BFRIW | Biofrontera Inc |
| 14/11/2022 | 14:45 | GlobeNewswire Inc. | Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update | NASDAQ:BFRIW | Biofrontera Inc |
| 10/11/2022 | 17:52 | GlobeNewswire Inc. | Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022 | NASDAQ:BFRIW | Biofrontera Inc |
| 08/11/2022 | 22:45 | GlobeNewswire Inc. | Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares of Biofrontera AG | NASDAQ:BFRIW | Biofrontera Inc |
| 31/10/2022 | 13:55 | GlobeNewswire Inc. | Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG | NASDAQ:BFRIW | Biofrontera Inc |
| 24/10/2022 | 13:45 | GlobeNewswire Inc. | Biofrontera Inc. Names Fred Leffler as Chief Financial Officer | NASDAQ:BFRIW | Biofrontera Inc |
| 20/10/2022 | 17:40 | GlobeNewswire Inc. | Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference | NASDAQ:BFRIW | Biofrontera Inc |
| 18/10/2022 | 16:30 | GlobeNewswire Inc. | Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference | NASDAQ:BFRIW | Biofrontera Inc |
| 14/10/2022 | 14:40 | GlobeNewswire Inc. | Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan | NASDAQ:BFRIW | Biofrontera Inc |
| 12/10/2022 | 20:00 | GlobeNewswire Inc. | BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022 | NASDAQ:BFRIW | Biofrontera Inc |
